阿那莫林和普拉替尼联用的治疗优势？

The therapeutic advantages of combining anamorelin and platinib are mainly synergistic anti-tumor effects, enhanced therapeutic effects, improved quality of life, personalized treatment, and effective reduction of drug resistance.

Therapeutic advantages of combining anamorelin and platinib

1. Synergistic anti-tumor effect: Anamorelin may help improve patients' tolerance and response to anti-tumor treatments such as platinib by improving patients' nutritional status and quality of life.

2. Enhance the therapeutic effect: The anti-tumor effect of platinib may be combined with the improvement of the systemic condition of anamorelin to jointly improve the therapeutic effect.

3. Improve quality of life: Anamorelin may help reduce symptoms related to cancer cachexia, such as weight loss and loss of appetite, thereby improving the overall quality of life of lung cancer patients.

4. Personalized treatment: Combining these two drugs may provide more personalized treatment options for patients with certain types of cancer.

5. Effectively reduce drug resistance: It can effectively reduce the occurrence of drug resistance. By simultaneously targeting multiple key signaling pathways of tumor cells, the treatment effect can be improved and the development of drug resistance can be delayed.

About Anamorelin

Specially targeted at cachexia, which has a high incidence rate in patients with malignant tumors. 50%-80% of patients will experience varying degrees of cachexia, and about 30% of them die due to weight loss caused by cancer cachexia. Anamorelin can effectively increase patients' appetite, improve muscle mass, and increase weight. It has long-lasting efficacy and good safety. It can indirectly increase the absorption of targeted drugs in the body and contribute to disease control.

Japanese regulatory authorities approved anamorelin for the treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer.

About Platinib

Pralsetinib is used to treat adult patients with transfection gene (RET) fusion-positive non-small cell lung cancer with metastatic rearrangements during the cancer process. Platinib can inhibit the phosphorylation of RET and its downstream molecules, effectively inhibiting the proliferation of cells expressing RET gene mutations.

The efficacy of anamorelin

A phase 2 trial in patients with non-small cell lung cancer and cachexia showed that anamorelin could increase the patient's lean body weight by 1.56kg. Compared with the placebo group, the changes in lean body mass, body weight and anorexia symptoms in the anamorelin treatment group showed significant differences. Another study in advanced unresectable gastrointestinal cancer showed that lean body mass improved by 1.89 ± 0.36 kg after anamorelin treatment as assessed by DXA. Most studies show a significant increase in lean body mass as assessed by DXA.

Medicine Guidelines for Anamorelin

The usual adult dose of Anamorelin is 100 mg, taken orally once a day on an empty stomach. If no effect is observed 3 weeks after the start of administration, the administration will be stopped. There is no experience of taking it for more than 12 weeks. Additionally, anamorelin should be used under the supervision of a physician with adequate knowledge and experience in cancer cachexia. The risks and benefits of medication should be fully explained before use and ensure that the patient or family understands them.

(Note: The above dosage and administration reference are from Japanese drug instructions. The usage and dosage are for reference only, and the specific instructions need to be subject to medical advice)

As an example of the risks associated with anamorelin, cardiac risks such as QT interval prolongation may occur. In addition, this drug is contraindicated in patients with a history of hypersensitivity to any component of the drug or in patients taking the drug concurrently.

Summary

In actual clinical applications, doctors will decide whether to use anamorelin and platinib combination therapy based on the patient's specific situation and cancer type, and closely monitor the patient's response and potential side effects.

Recommended hot articles: